Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484308 | 0.94 | EGFR (0.36) | EGFR | |
| SCHEMBL1482879 | 0.83 | PIM1 (0.35) | — | |
| SCHEMBL1484311 | 0.74 | EGFR (0.40) | EGFR | |
| SCHEMBL1483470 | 0.74 | ERN1 (0.35) | — | |
| SCHEMBL1482972 | 0.73 | EGFR (0.39) | EGFR | |
| SCHEMBL1483355 | 0.73 | POLB (0.38) | — | |
| SCHEMBL15477801 | 0.71 | EGFR (0.36) | EGFR | |
| SCHEMBL1483267 | 0.71 | EGFR (0.36) | EGFR | |
| SCHEMBL1483351 | 0.71 | EGFR (0.38) | EGFR | |
| SCHEMBL1483571 | 0.70 | EGFR (0.34) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |